Download PDF

1. Company Snapshot

1.a. Company Description

Formycon AG develops and markets biosimilar products.Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials.The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19.


It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline.The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012.Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Show Full description

1.b. Last Insights on FYB

Formycon AG's recent performance has been positively driven by strategic advances, including a significant partnership with MS Pharma for the commercialization of its Keytruda biosimilar candidate, FYB206, in the Middle East and North Africa region. This deal includes an option for future technology transfer, potentially boosting growth. Additionally, the company's Q3 2025 earnings call highlighted notable clinical and operational progress. As a growth company with high insider ownership, Formycon's strong internal confidence in its growth potential may appeal to investors.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region

Dec -04

Source:

Card image cap

European Growth Companies With High Insider Ownership To Watch

Nov -27

Source:

Card image cap

Formycon AG (XTER:FYB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges

Nov -13

Source:

Card image cap

3 European Growth Stocks With Strong Insider Ownership

Oct -29

Source:

Card image cap

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Oct -21

Source:

Card image cap

European Growth Stocks With Strong Insider Ownership In September 2025

Sep -29

Source:

Card image cap

European Growth Companies With High Insider Ownership Expecting Up To 97% Earnings Growth

Aug -28

Source:

Card image cap

Formycon Invites to Conference Call on 2025 Half-year Results and Announces Participation in International Investor Conferences in the 3rd Quarter of 2025

Jul -30

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.72%)

6. Segments

FYB202

Expected Growth: 8.5%

Formycon AG's FYB202 growth of 8.5% is driven by increasing demand for biosimilar products, expansion into new markets, and strategic partnerships. The company's strong R&D pipeline, cost-effective manufacturing process, and growing presence in the ophthalmology segment also contribute to its growth momentum.

FYB201

Expected Growth: 9.27%

Formycon AG's FYB201 growth of 9.27% is driven by increasing demand for biosimilar products, successful partnerships, and strategic expansion into new markets. Additionally, the company's focus on R&D and innovative pipeline products contributes to its growth momentum.

7. Detailed Products

Formycon Biotherapeutics

Formycon AG develops high-quality biosimilars, which are biotechnologically produced medications that are similar to reference products, but at a lower cost.

Formycon Ophthalmology

Formycon AG develops innovative ophthalmology products, including biosimilars and biobetters, to treat eye diseases such as age-related macular degeneration and diabetic retinopathy.

Formycon Oncology

Formycon AG develops innovative oncology products, including biosimilars and biobetters, to treat various types of cancer.

Formycon Immunology

Formycon AG develops innovative immunology products, including biosimilars and biobetters, to treat autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

8. Formycon AG's Porter Forces

Forces Ranking

Threat Of Substitutes

Formycon AG operates in a niche market with limited substitutes, but there are some alternatives available, which reduces the threat of substitutes.

Bargaining Power Of Customers

Formycon AG's customers are mainly pharmaceutical companies, which have limited bargaining power due to the company's specialized products and services.

Bargaining Power Of Suppliers

Formycon AG relies on a few key suppliers for raw materials, which gives them some bargaining power, but the company's specialized products and services reduce their dependence on suppliers.

Threat Of New Entrants

The biotech industry has high barriers to entry, including significant capital requirements and regulatory hurdles, which reduces the threat of new entrants.

Intensity Of Rivalry

The biotech industry is highly competitive, with many established players and new entrants vying for market share, which increases the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 5.54%
Debt Cost 3.95%
Equity Weight 94.46%
Equity Cost 8.10%
WACC 7.87%
Leverage 5.86%

11. Quality Control: Formycon AG passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Idorsia

A-Score: 5.1/10

Value: 8.4

Growth: 6.8

Quality: 5.2

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Centessa Pharmaceuticals

A-Score: 3.9/10

Value: 6.0

Growth: 3.9

Quality: 4.7

Yield: 0.0

Momentum: 8.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Barinthus Bio

A-Score: 3.5/10

Value: 8.4

Growth: 4.8

Quality: 3.4

Yield: 0.0

Momentum: 4.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Calliditas Therapeutics

A-Score: 3.0/10

Value: 6.0

Growth: 4.2

Quality: 3.8

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Atrys Health

A-Score: 2.7/10

Value: 6.0

Growth: 3.7

Quality: 1.9

Yield: 0.0

Momentum: 1.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Formycon

A-Score: 2.2/10

Value: 6.0

Growth: 2.2

Quality: 3.4

Yield: 0.0

Momentum: 0.0

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

24.95$

Current Price

24.95$

Potential

-0.00%

Expected Cash-Flows